Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 8/20 | 0.44 |
| ▸ | CHRM1 known ✓ | P11229 | 7/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5133743 | 0.99 | CHRM3 (0.44) | CHRM3CHRM2CHRM1 | |
| Iodide SCHEMBL3038138 | 0.99 | CHRM3 (0.44) | CHRM3CHRM2CHRM1 | |
| Iodide SCHEMBL3046849 | 0.93 | CHRM3 (0.46) | CHRM3CHRM2CHRM1 | |
| SCHEMBL5133252 | 0.92 | CHRM3 (0.46) | CHRM3CHRM2CHRM1 | |
| Iodide SCHEMBL3052160 | 0.86 | CHRM2 (0.55) | CHRM3CHRM2CHRM1 | |
| Iodide SCHEMBL2795185 | 0.83 | HTT (0.62) | CHRM3CHRM2CHRM1 | |
| Iodide SCHEMBL3043395 | 0.82 | CHRM3 (0.42) | CHRM3CHRM2CHRM1 | |
| Iodide SCHEMBL3049337 | 0.82 | HTT (0.60) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL2795780 | 0.81 | HTT (0.62) | CHRM3CHRM2CHRM1 | |
| Iodide SCHEMBL3035535 | 0.81 | ALDH1A1 (0.44) | CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222393-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-09-02 | — | — | US | claimed |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-07 | — | — | US | claimed |
| EP-2111861-A1 | Compositions of phosphodiesterase type IV inhibitors | Ranbaxy Laboratories Limited (IN) | 2009-10-28 | — | — | EP | claimed |
| EP-2225253-A1 | PHOSPHONIC ACID DERIVATES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2010-09-08 | — | — | EP | disclosed |
| US-20100222393-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-09-02 | — | — | US | disclosed |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-07 | — | — | US | disclosed |
| EP-2111861-A1 | Compositions of phosphodiesterase type IV inhibitors | Ranbaxy Laboratories Limited (IN) | 2009-10-28 | — | — | EP | disclosed |
| WO-2009069100-A1 | PHOSPHONIC ACID DERIVATES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-04 | — | — | WO | disclosed |
| EP-1968945-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007077510-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222393-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM1 | CHRM3 1/4885CHRM1 3/4885CHRM2 2/4885 |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | PDE4B, PDE4A, PDE3B | CHRM3 88/4885CHRM1 158/4885CHRM2 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.